In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing

ABSTRACT We evaluated the MICs of isavuconazole (ISAV) against 96 isolates of Aspergillus species and 36 zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. In addition, the in vitro activity was obtained for hyphal inocula. ISAV exhibited good antifungal activity against the tested isolates with the exception of Aspergillus niger and Mucorales. The in vitro activity of ISAV was comparable to that of voriconazole aside from Mucorales.

[1]  D. Denning,et al.  Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. , 2009 .

[2]  Subcommittee on Antifungal Susceptibility Testing EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  J. Pemán,et al.  Activity of BAL 4815 against filamentous fungi. , 2008, The Journal of antimicrobial chemotherapy.

[4]  T. Peláez,et al.  In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species , 2008, Antimicrobial Agents and Chemotherapy.

[5]  D. Denning,et al.  EUCAST DEFINITIVE DOCUMENT E.DEF 9.1: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds , 2008 .

[6]  D. Denning,et al.  New and emerging treatments for fungal infections. , 2008, The Journal of antimicrobial chemotherapy.

[7]  N. Kiraz,et al.  In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole , 2007, Mycoses.

[8]  D. Denning,et al.  Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. , 2006, The Journal of antimicrobial chemotherapy.

[9]  M. Dierich,et al.  Posaconazole Enhances the Activity of Amphotericin B against Aspergillus Hyphae In Vitro , 2006, Antimicrobial Agents and Chemotherapy.

[10]  F. Odds Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal. , 2006, Current opinion in investigational drugs.

[11]  M. J. Buitrago,et al.  Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi , 2006, Antimicrobial Agents and Chemotherapy.

[12]  A. Schmitt-Hoffmann,et al.  Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers , 2006, Antimicrobial Agents and Chemotherapy.

[13]  D. Denning,et al.  In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. , 2006, The Journal of antimicrobial chemotherapy.

[14]  T J Walsh,et al.  Infections due to emerging and uncommon medically important fungal pathogens. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  M. Boogaerts,et al.  Caspofungin in the treatment of candidosis and aspergillosis. , 2003, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[16]  M. Rinaldi,et al.  Optimal Testing Conditions for Determining MICs and Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Uncommon Molds: NCCLS Collaborative Study , 2002, Journal of Clinical Microbiology.

[17]  J. Peter,et al.  Testing Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative Study , 2002, Journal of Clinical Microbiology.

[18]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[19]  H. Ulmer,et al.  In vitro studies on the activity of amphotericin B and lipid‐based amphotericin B formulations against Aspergillus conidia and hyphae
 , 2002, Mycoses.

[20]  M. Dierich,et al.  Studies of In Vitro Activities of Voriconazole and Itraconazole against Aspergillus Hyphae Using Viability Staining , 2001, Antimicrobial Agents and Chemotherapy.

[21]  S. Levitz,et al.  A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. , 1985, The Journal of infectious diseases.